Global and China Targeted Drug VEGF Inhibitors for NSCLC Market Size, Status and Forecast 2021-2027

SKU ID : QYR-19139572 | Publishing Date : 13-Sep-2021 | No. of pages : 107

Detailed TOC of Global and China Targeted Drug VEGF Inhibitors for NSCLC Market Size, Status and Forecast 2021-2027

1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Bevacizumab
        1.2.3 Other
    1.3 Market by Application
        1.3.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Squamous Cell Carcinoma of NSCLC
        1.3.3 Adenocarcinoma of NSCLC
        1.3.4 Large Cell Carcinoma of NSCLC
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Perspective (2016-2027)
    2.2 Targeted Drug VEGF Inhibitors for NSCLC Growth Trends by Regions
        2.2.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Targeted Drug VEGF Inhibitors for NSCLC Historic Market Share by Regions (2016-2021)
        2.2.3 Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Regions (2022-2027)
    2.3 Targeted Drug VEGF Inhibitors for NSCLC Industry Dynamic
        2.3.1 Targeted Drug VEGF Inhibitors for NSCLC Market Trends
        2.3.2 Targeted Drug VEGF Inhibitors for NSCLC Market Drivers
        2.3.3 Targeted Drug VEGF Inhibitors for NSCLC Market Challenges
        2.3.4 Targeted Drug VEGF Inhibitors for NSCLC Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Targeted Drug VEGF Inhibitors for NSCLC Players by Revenue
        3.1.1 Global Top Targeted Drug VEGF Inhibitors for NSCLC Players by Revenue (2016-2021)
        3.1.2 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Players (2016-2021)
    3.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Targeted Drug VEGF Inhibitors for NSCLC Revenue
    3.4 Global Targeted Drug VEGF Inhibitors for NSCLC Market Concentration Ratio
        3.4.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Targeted Drug VEGF Inhibitors for NSCLC Revenue in 2020
    3.5 Targeted Drug VEGF Inhibitors for NSCLC Key Players Head office and Area Served
    3.6 Key Players Targeted Drug VEGF Inhibitors for NSCLC Product Solution and Service
    3.7 Date of Enter into Targeted Drug VEGF Inhibitors for NSCLC Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Targeted Drug VEGF Inhibitors for NSCLC Breakdown Data by Type
    4.1 Global Targeted Drug VEGF Inhibitors for NSCLC Historic Market Size by Type (2016-2021)
    4.2 Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Type (2022-2027)

5 Targeted Drug VEGF Inhibitors for NSCLC Breakdown Data by Application
    5.1 Global Targeted Drug VEGF Inhibitors for NSCLC Historic Market Size by Application (2016-2021)
    5.2 Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027)
    6.2 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
        6.2.1 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2021)
        6.2.2 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2022-2027)
        6.2.3 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2027)
    6.3 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
        6.3.1 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2016-2021)
        6.3.2 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2022-2027)
        6.3.3 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2016-2027)
    6.4 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country
        6.4.1 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2016-2021)
        6.4.2 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027)
    7.2 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
        7.2.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2021)
        7.2.2 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2022-2027)
        7.2.3 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2027)
    7.3 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
        7.3.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2016-2021)
        7.3.2 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2022-2027)
        7.3.3 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2016-2027)
    7.4 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country
        7.4.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2016-2021)
        7.4.2 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027)
    8.2 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
        8.2.1 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2027)
    8.3 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
        8.3.1 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2016-2027)
    8.4 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region
        8.4.1 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027)
    9.2 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
        9.2.1 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2021)
        9.2.2 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2022-2027)
        9.2.3 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2027)
    9.3 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
        9.3.1 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2016-2021)
        9.3.2 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2022-2027)
        9.3.3 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2016-2027)
    9.4 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country
        9.4.1 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2016-2021)
        9.4.2 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size (2016-2027)
    10.2 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
        10.2.1 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2027)
    10.3 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
        10.3.1 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2016-2027)
    10.4 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country
        10.4.1 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Roche
        11.1.1 Roche Company Details
        11.1.2 Roche Business Overview
        11.1.3 Roche Targeted Drug VEGF Inhibitors for NSCLC Introduction
        11.1.4 Roche Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
        11.1.5 Roche Recent Development
    11.2 Pfizer
        11.2.1 Pfizer Company Details
        11.2.2 Pfizer Business Overview
        11.2.3 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Introduction
        11.2.4 Pfizer Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
        11.2.5 Pfizer Recent Development
    11.3 Allergan
        11.3.1 Allergan Company Details
        11.3.2 Allergan Business Overview
        11.3.3 Allergan Targeted Drug VEGF Inhibitors for NSCLC Introduction
        11.3.4 Allergan Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
        11.3.5 Allergan Recent Development
    11.4 Amgen
        11.4.1 Amgen Company Details
        11.4.2 Amgen Business Overview
        11.4.3 Amgen Targeted Drug VEGF Inhibitors for NSCLC Introduction
        11.4.4 Amgen Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
        11.4.5 Amgen Recent Development
    11.5 Biocon
        11.5.1 Biocon Company Details
        11.5.2 Biocon Business Overview
        11.5.3 Biocon Targeted Drug VEGF Inhibitors for NSCLC Introduction
        11.5.4 Biocon Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
        11.5.5 Biocon Recent Development
    11.6 Reliance Lifesciences
        11.6.1 Reliance Lifesciences Company Details
        11.6.2 Reliance Lifesciences Business Overview
        11.6.3 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Introduction
        11.6.4 Reliance Lifesciences Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
        11.6.5 Reliance Lifesciences Recent Development
    11.7 Beaconpharma
        11.7.1 Beaconpharma Company Details
        11.7.2 Beaconpharma Business Overview
        11.7.3 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Introduction
        11.7.4 Beaconpharma Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
        11.7.5 Beaconpharma Recent Development
    11.8 Celgene Corporation
        11.8.1 Celgene Corporation Company Details
        11.8.2 Celgene Corporation Business Overview
        11.8.3 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Introduction
        11.8.4 Celgene Corporation Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
        11.8.5 Celgene Corporation Recent Development
    11.9 Fujifilm Kyowa Kirin Biologics
        11.9.1 Fujifilm Kyowa Kirin Biologics Company Details
        11.9.2 Fujifilm Kyowa Kirin Biologics Business Overview
        11.9.3 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Introduction
        11.9.4 Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
        11.9.5 Fujifilm Kyowa Kirin Biologics Recent Development
    11.10 Hetero Drugs
        11.10.1 Hetero Drugs Company Details
        11.10.2 Hetero Drugs Business Overview
        11.10.3 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Introduction
        11.10.4 Hetero Drugs Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
        11.10.5 Hetero Drugs Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Figures, Tables and Charts Available in Global and China Targeted Drug VEGF Inhibitors for NSCLC Market Size, Status and Forecast 2021-2027

List of Tables
    Table 1. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Bevacizumab
    Table 3. Key Players of Other
    Table 4. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 5. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Regions (2016-2021) & (US$ Million)
    Table 7. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Regions (2016-2021)
    Table 8. Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 9. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Regions (2022-2027)
    Table 10. Targeted Drug VEGF Inhibitors for NSCLC Market Trends
    Table 11. Targeted Drug VEGF Inhibitors for NSCLC Market Drivers
    Table 12. Targeted Drug VEGF Inhibitors for NSCLC Market Challenges
    Table 13. Targeted Drug VEGF Inhibitors for NSCLC Market Restraints
    Table 14. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by Players (2016-2021) & (US$ Million)
    Table 15. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Players (2016-2021)
    Table 16. Global Top Targeted Drug VEGF Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drug VEGF Inhibitors for NSCLC as of 2020)
    Table 17. Ranking of Global Top Targeted Drug VEGF Inhibitors for NSCLC Companies by Revenue (US$ Million) in 2020
    Table 18. Global 5 Largest Players Market Share by Targeted Drug VEGF Inhibitors for NSCLC Revenue (CR5 and HHI) & (2016-2021)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Targeted Drug VEGF Inhibitors for NSCLC Product Solution and Service
    Table 21. Date of Enter into Targeted Drug VEGF Inhibitors for NSCLC Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 24. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Type (2016-2021)
    Table 25. Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 26. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 27. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Share by Application (2016-2021) & (US$ Million)
    Table 28. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Application (2016-2021)
    Table 29. Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 30. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 31. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 32. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2022-2027) & (US$ Million)
    Table 33. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2016-2021) (US$ Million)
    Table 34. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2022-2027) & (US$ Million)
    Table 35. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2016-2021) & (US$ Million)
    Table 36. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2022-2027) & (US$ Million)
    Table 37. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 38. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2022-2027) & (US$ Million)
    Table 39. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2016-2021) (US$ Million)
    Table 40. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2022-2027) & (US$ Million)
    Table 41. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2016-2021) & (US$ Million)
    Table 42. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2022-2027) & (US$ Million)
    Table 43. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 44. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2022-2027) & (US$ Million)
    Table 45. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2016-2021) & (US$ Million)
    Table 48. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2022-2027) & (US$ Million)
    Table 49. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 50. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2022-2027) & (US$ Million)
    Table 51. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2016-2021) (US$ Million)
    Table 52. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2022-2027) & (US$ Million)
    Table 53. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2016-2021) & (US$ Million)
    Table 54. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2022-2027) & (US$ Million)
    Table 55. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 56. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2022-2027) & (US$ Million)
    Table 57. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2016-2021) & (US$ Million)
    Table 60. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2022-2027) & (US$ Million)
    Table 61. Roche Company Details
    Table 62. Roche Business Overview
    Table 63. Roche Targeted Drug VEGF Inhibitors for NSCLC Product
    Table 64. Roche Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 65. Roche Recent Development
    Table 66. Pfizer Company Details
    Table 67. Pfizer Business Overview
    Table 68. Pfizer Targeted Drug VEGF Inhibitors for NSCLC Product
    Table 69. Pfizer Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 70. Pfizer Recent Development
    Table 71. Allergan Company Details
    Table 72. Allergan Business Overview
    Table 73. Allergan Targeted Drug VEGF Inhibitors for NSCLC Product
    Table 74. Allergan Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 75. Allergan Recent Development
    Table 76. Amgen Company Details
    Table 77. Amgen Business Overview
    Table 78. Amgen Targeted Drug VEGF Inhibitors for NSCLC Product
    Table 79. Amgen Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 80. Amgen Recent Development
    Table 81. Biocon Company Details
    Table 82. Biocon Business Overview
    Table 83. Biocon Targeted Drug VEGF Inhibitors for NSCLC Product
    Table 84. Biocon Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 85. Biocon Recent Development
    Table 86. Reliance Lifesciences Company Details
    Table 87. Reliance Lifesciences Business Overview
    Table 88. Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Product
    Table 89. Reliance Lifesciences Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 90. Reliance Lifesciences Recent Development
    Table 91. Beaconpharma Company Details
    Table 92. Beaconpharma Business Overview
    Table 93. Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Product
    Table 94. Beaconpharma Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 95. Beaconpharma Recent Development
    Table 96. Celgene Corporation Company Details
    Table 97. Celgene Corporation Business Overview
    Table 98. Celgene Corporation Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 99. Celgene Corporation Recent Development
    Table 100. Fujifilm Kyowa Kirin Biologics Company Details
    Table 101. Fujifilm Kyowa Kirin Biologics Business Overview
    Table 102. Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Product
    Table 103. Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 104. Fujifilm Kyowa Kirin Biologics Recent Development
    Table 105. Hetero Drugs Company Details
    Table 106. Hetero Drugs Business Overview
    Table 107. Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Product
    Table 108. Hetero Drugs Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021) & (US$ Million)
    Table 109. Hetero Drugs Recent Development
    Table 110. Research Programs/Design for This Report
    Table 111. Key Data Information from Secondary Sources
    Table 112. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type: 2020 VS 2027
    Figure 2. Bevacizumab Features
    Figure 3. Other Features
    Figure 4. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application: 2020 VS 2027
    Figure 5. Squamous Cell Carcinoma of NSCLC Case Studies
    Figure 6. Adenocarcinoma of NSCLC Case Studies
    Figure 7. Large Cell Carcinoma of NSCLC Case Studies
    Figure 8. Targeted Drug VEGF Inhibitors for NSCLC Report Years Considered
    Figure 9. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 10. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 11. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Regions: 2020 VS 2027
    Figure 12. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Regions (2022-2027)
    Figure 13. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Players in 2020
    Figure 14. Global Top Targeted Drug VEGF Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drug VEGF Inhibitors for NSCLC as of 2020
    Figure 15. The Top 10 and 5 Players Market Share by Targeted Drug VEGF Inhibitors for NSCLC Revenue in 2020
    Figure 16. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Type (2016-2021)
    Figure 17. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Type (2022-2027)
    Figure 18. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 19. North America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2016-2027)
    Figure 20. North America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2016-2027)
    Figure 21. North America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Country (2016-2027)
    Figure 22. United States Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 23. Canada Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2016-2027)
    Figure 26. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2016-2027)
    Figure 27. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Share by Country (2016-2027)
    Figure 28. Germany Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 29. France Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. U.K. Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. Italy Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Russia Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Nordic Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2016-2027)
    Figure 36. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2016-2027)
    Figure 37. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Share by Region (2016-2027)
    Figure 38. China Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. South Korea Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. India Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Australia Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2016-2027)
    Figure 46. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2016-2027)
    Figure 47. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Country (2016-2027)
    Figure 48. Mexico Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. Brazil Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2016-2027)
    Figure 52. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2016-2027)
    Figure 53. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Share by Country (2016-2027)
    Figure 54. Turkey Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 55. Saudi Arabia Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. UAE Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. Roche Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
    Figure 58. Pfizer Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
    Figure 59. Allergan Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
    Figure 60. Amgen Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
    Figure 61. Biocon Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
    Figure 62. Reliance Lifesciences Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
    Figure 63. Beaconpharma Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
    Figure 64. Celgene Corporation Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
    Figure 65. Fujifilm Kyowa Kirin Biologics Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
    Figure 66. Hetero Drugs Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2016-2021)
    Figure 67. Bottom-up and Top-down Approaches for This Report
    Figure 68. Data Triangulation
    Figure 69. Key Executives Interviewed

Keyplayers in Global and China Targeted Drug VEGF Inhibitors for NSCLC Market Size, Status and Forecast 2021-2027

Roche
Pfizer
Allergan
Amgen
Biocon
Reliance Lifesciences
Beaconpharma
Celgene Corporation
Fujifilm Kyowa Kirin Biologics
Hetero Drugs

REQUEST SUMMARY

Request Sample

Pre-order Enquiry

Request Discount

Contact Information

24/7 Research Support

Phone: +1 424 253 0807

[email protected]